To solve the controversy, a meta-analysis in 2014 was published and suggested that FOXP3 rs3761549 (T/C) and rs3761548 (A/C) polymorphisms were not associated with the risk of breast cancer, but with the risk of lung cancer and hepatocellular cancer [21]. The gene discussed is FOXP3; the disease is breast carcinoma.